Ocular powder: Dry topical formulations of timolol are well tolerated in rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 5, 2006, Pages 340-346

  Hardarson, Sveinn Hákon ^a   Sigurdsson, Hákon Hrafn ^a   Níelsdóttir, Gudrún Eva ^a   Valgeirsson, Jón ^b   Loftsson, Thorsteinn ^a   Stefánsson, Einar ^a,c  

^a UNIVERSITY OF ICELAND   (Iceland)

^b Actavis Group   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER; POVIDONE; PRESERVATIVE; TIMOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG TOLERABILITY; DRY POWDER; EYE IRRITATION; FREEZE DRYING; GLAUCOMA; NONHUMAN; PHOTOGRAPHY; RABBIT; SLIT LAMP; SURFACE PROPERTY;

ANIMALS; AQUEOUS HUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EYE; FEASIBILITY STUDIES; FEMALE; MALE; POWDERS; RABBITS; REPRODUCIBILITY OF RESULTS; TIMOLOL;

EID: 33750682713     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.340     Document Type: Article

References (27)

1. Edwards, A., and Prausnitz, M.R. Predicted permeability of the cornea to topical drugs. Pharm. Res. 18:1497-1508, 2001.
2. Prausnitz, M.R., and Noonan, J.S. Permeability of cornea, sciera, and conjunctiva: A literature analysis for drug delivery to the eye. J. Pharm. Sci. 87:1479-1488, 1998.
3. Jarvinen, K., Jarvinen, T., and Urtti, A. Ocular absorption following topical delivery. Adv. Drug Deliv. Rev. 16:3-19, 1995.
4. Urtti, A., and Salminen, L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37:435-156, 1993.
5. Ahmed, I., and Patton, T.F. Importance of the non-corneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26:584-587, 1985.
6. Chien, D.S., Homsy, J.J., Gluchowski, C., et al. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res. 9:1051-1059, 1990.
7. Schoenwald, R.D., Deshpande, G.S., Rethwisch, D.G., et al. Penetration into the anterior chamber via the conjunctival/scierai pathway. J. Ocul. Pharmacol. Ther. 13:41-59, 1997.
8. Mishima, S., Gasset, A., Klyce, S.D., Jr., et al. Determination of tear volume and tear flow. Invest. Ophthalmol. 5:264-276, 1966.
9. Wilson, C.G. Topical drug delivery in the eye. Exp. Eye Res. 78:737-743, 2004.
10. Baudouin, C., Pisella, P.J., Fillacier, K., et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: Human and animal studies. Ophthalmology 106:556-563, 1999.
11. Becquet, F., Goldschild, M., Moldovan, M.S., et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr. Eye Res. 17:419-125, 1998.
12. Grant, W., and Schuman, J.S. Toxicology of the Eye. Springfield, IL: Charles C. Thomas, 1993.
13. Pisella, P.J., Pouliquen, P., and Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br. J. Ophthalmol. 86:418-423, 2002.
14. Wilhelmus, K.R. The Draize eye test. Surv. Ophthalmol. 45:493-515, 2001.
15. Stewart, W.C., Kolker, A.E., Stewart, J.A., et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am. J. Ophthalmol. 135:314-320, 2003.
16. Edelhauser, H.F., and Maren, T.H. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch. Ophthalmol. 106:1110-1115, 1988.
17. Seabaugh, V.M., Chambers, W.A., Green, S., et al. Use of ophthalmic topical anaesthetics. Food Chem. Toxicol. 31:95-98, 1993.
18. Thornton, C.N., and Hanna, C. Mydriasis from topically administered phenylephrine HCl powder. Am. J. Ophthalmol. 89:809-813, 1980.
19. Gwon, A., Borrmann, L.R., Duzman, E., et al. Ophthalmic rods. New ocular drug delivery devices. Ophthalmology 93:82-85, 1986.
20. Diestelhorst, M., Grunthal, S., and Suverkrup, R. Dry Drops: A new preservative-free drug delivery system. Graefe's Arch. Clin. Exp. Ophthalmol. 237:394-398, 1999.
21. Dinslage, S., Diestelhorst, M., Weichselbaum, A., et al. Lyophilisates for drug delivery in ophthalmology: Pharmacokinetics of fluorescein in the human anterior segment. Br. J. Ophthalmol. 86:1114-1117, 2002.
22. Lux, A., Maier, S., Dinslage, S., et al. A comparative bioavailability study of three conventional eye drops versus a single lyophilisate. Br. J. Ophthalmol. 87:436-440, 2003.
23. Steinfeld, A., Lux, A., Maier, S., et al. Bioavailability of fluorescein from a new drug delivery system in human eyes. Br. J. Ophthalmol. 88:48-53, 2004.
24. Suverkrup, R., Grunthal, S., Krasichkova, O., et al. The ophthalmic lyophilisate carrier system (OLCS): Development of a novel dosage form, freeze-drying technique, and in vitro quality control tests. Eur. J. Pharm. Biopharm. 57:269-277, 2004.
25. Suverkrup, R., Weichselbaum, A., and Diestelhorst, M. Pilocarpine dry drops: Miotic effect and discomfort upon administration compared to conventional eyedrops. Invest. Ophthalmol. 40:S85, 1999.
26. Weichselbaum, A., Dinslage, S., Suverkrup, R., et al. Tropicamide lyophilized eyedrops-time course of mydriatic effect and tolerability compared to conventional eyedrops. Invest. Ophthalmol. 41:S767, 2000.
27. Lederer, C.M., Jr., and Harold, R.E. Drop size of commercial glaucoma medications. Am. J. Ophthalmol. 101:691-694, 1986.